AMPH
Amphastar Pharmaceuticals, Inc.Company Information
- Company Name
- Amphastar Pharmaceuticals, Inc.
- CIK
- CIK0001297184
- Category
- Large accelerated filer
- Ticker: Exchange
- AMPH: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- AMPH
SEC filing data through
Insider Sentiment
- Last purchase
- —
- Last sale
- 2026-09-21
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 67,550
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 26,971,936
- Shares outstanding
- 43,644,000
- Ownership
- 61.80%
Earnings Market Reaction
- Filing date
- 2026-08-06
- Price on filing date
- —
- 1-month reaction
- 11.11%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 224 | 171 | 170 | 216 | 188 | 183 | 152 | 192 | 190 | 201 | 144 | 267 | ||||||
| Restricted Cash Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | ||||||
| Short Term Investments | 67 | 121 | 113 | 60 | 44 | 54 | 70 | 58 | 28 | 88 | 113 | 33 | ||||||
| Restricted Investments Current | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | ||||||
| Accounts Receivable Net Current | 145 | 148 | 144 | 147 | 133 | 145 | 136 | 140 | 131 | 138 | 115 | 119 | ||||||
| Inventory Net | 180 | 170 | 177 | 186 | 192 | 185 | 154 | 130 | 122 | 115 | 106 | 110 | ||||||
| Prepaid Expense And Other Assets Current | 11 | 12 | 13 | 26 | 20 | 18 | 18 | 18 | 8 | 9 | 9 | 6 | ||||||
| Assets Current | 631 | 634 | 636 | 639 | 581 | 588 | 534 | 546 | 483 | 555 | 490 | 543 | ||||||
| Property Plant And Equipment Net | 316 | 307 | 311 | 309 | 310 | 308 | 297 | 295 | 288 | 289 | 283 | 281 | ||||||
| Finance Lease Right Of Use Asset | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | ||||||
| Operating Lease Right Of Use Asset | 73 | 71 | 43 | 45 | 44 | 46 | 47 | 32 | 32 | 31 | 32 | 33 | ||||||
| Intangible Assets Net Including Goodwill | 648 | 560 | 566 | 572 | 578 | 585 | 591 | 595 | 601 | 607 | 613 | 619 | ||||||
| Long Term Investments | - | - | - | - | 2 | 6 | 11 | - | 10 | 15 | 15 | 1 | ||||||
| Other Assets Noncurrent | 33 | 33 | 31 | 30 | 28 | 23 | 26 | 24 | 24 | 23 | 26 | 25 | ||||||
| Deferred Income Tax Assets Net | 42 | 42 | 42 | 71 | 71 | 71 | 71 | 53 | 53 | 53 | 53 | 41 | ||||||
| Assets | 1,744 | 1,648 | 1,629 | 1,666 | 1,615 | 1,626 | 1,577 | 1,545 | 1,492 | 1,574 | 1,513 | 1,545 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable And Accrued Liabilities Current | 251 | 153 | 148 | 191 | 167 | 176 | 157 | 153 | 131 | 117 | 93 | 223 | ||||||
| Accrued Income Taxes Current | 1 | 0 | 0 | 6 | 1 | 15 | 10 | 1 | 2 | 6 | 2 | 31 | ||||||
| Long Term Debt And Capital Lease Obligations Current | 2 | 2 | 2 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Operating Lease Liability Current | 9 | 10 | 8 | 8 | 8 | 8 | 7 | 4 | 4 | 4 | 4 | 4 | ||||||
| Liabilities Current | 263 | 164 | 158 | 205 | 176 | 199 | 174 | 159 | 137 | 255 | 225 | 258 | ||||||
| Accrued Income Taxes Noncurrent | 6 | 6 | 6 | 7 | 7 | 7 | 7 | 6 | 6 | 6 | 6 | 7 | ||||||
| Long Term Debt And Capital Lease Obligations | 610 | 610 | 609 | 609 | 608 | 604 | 602 | 596 | 587 | 594 | 590 | 638 | ||||||
| Operating Lease Liability Noncurrent | 67 | 65 | 38 | 39 | 39 | 41 | 42 | 29 | 29 | 29 | 30 | 30 | ||||||
| Deferred Income Tax Liabilities Net | - | - | - | - | - | - | - | - | - | - | - | 0 | ||||||
| Other Liabilities Noncurrent | 29 | 29 | 30 | 29 | 28 | 24 | 21 | 27 | 19 | 18 | 23 | 16 | ||||||
| Liabilities | 976 | 875 | 840 | 889 | 858 | 875 | 845 | 818 | 778 | 902 | 873 | 949 | ||||||
Stockholders Equity | ||||||||||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 553 | 544 | 535 | 527 | 521 | 509 | 505 | 496 | 488 | 476 | 486 | 478 | ||||||
| Retained Earnings Accumulated Deficit | 704 | 673 | 667 | 642 | 625 | 594 | 569 | 531 | 490 | 452 | 409 | 373 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -6 | -6 | -5 | -5 | -5 | -8 | -9 | -9 | -9 | -9 | -8 | -8 | ||||||
| Treasury Stock Value | -483 | -438 | -408 | -388 | -383 | -344 | -333 | -291 | -256 | -247 | -247 | -247 | ||||||
| Stockholders Equity | 768 | 773 | 789 | 777 | 757 | 751 | 732 | 728 | 713 | 672 | 639 | 595 | ||||||
| Liabilities And Stockholders Equity | 1,744 | 1,648 | 1,629 | 1,666 | 1,615 | 1,626 | 1,577 | 1,545 | 1,492 | 1,574 | 1,513 | 1,545 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | ||||||
| Common Stock Shares Issued | 62 | 62 | 62 | 62 | 62 | 61 | 61 | 61 | 60 | 60 | 59 | 59 | ||||||
| Shares Outstanding | 43 | 45 | 46 | 46 | 46 | 48 | 48 | 48 | 49 | 49 | 48 | 48 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialAmphastar Pharmaceuticals, Inc. (AMPH) — SEC Financial Statements & Analysis
Amphastar Pharmaceuticals, Inc. (AMPH) is a pharmaceutical preparations company. Amphastar Pharmaceuticals, Inc. trades on Nasdaq as: AMPH. Amphastar Pharmaceuticals, Inc. (AMPH)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06. Based on that filing, Amphastar Pharmaceuticals, Inc. carries a market cap of $880.74M, a P/E ratio of 11.21x, a P/B ratio of 1.15x, a P/S ratio of 1.21x, an enterprise value of $1.27B, and an EV/EBITDA multiple of 8.67x. On profitability, it posts a gross margin of 47.68%, an operating margin of 15.66%, a net margin of 10.76%, a Return on Equity (ROE) of 10.30%, a Return on Assets (ROA) of 4.68%, and a Return on Invested Capital (ROIC) of 7.45%. Per share, it reports EPS of $1.80, diluted EPS of $1.78, free cash flow per share of $3.50, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 1.02% year-over-year, net income growth of -63.61% year-over-year, and EPS growth of -60.85% year-over-year. On the balance sheet, it maintains a current ratio of 2.40x, a quick ratio of 1.67x, working capital of $367.75M, a debt-to-equity ratio of 1.27x, a debt ratio of 0.56, an interest coverage ratio of 4.37x, free cash flow of $152.89M (TTM), and net debt of $388.20M. Figures sourced from SEC EDGAR.
- Market Cap
- $880.74M
- P/E TTM
- 11.21x
- EPS TTM
- $1.80
- P/B TTM
- 1.15x
- ROE TTM
- 10.30%
- ROA TTM
- 4.68%
- Debt To Equity
- 1.27x
- Free Cash Flow TTM
- $152.89M
- Net Revenue TTM Growth 1Y
- 1.02%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Amphastar Pharmaceuticals, Inc. in?
Amphastar Pharmaceuticals, Inc. (AMPH) operates in the Pharmaceutical Preparations industry.
What exchange does AMPH trade on?
Amphastar Pharmaceuticals, Inc. (AMPH) trades on the Nasdaq.
When was Amphastar Pharmaceuticals, Inc. (AMPH)'s most recent SEC filing?
Amphastar Pharmaceuticals, Inc. (AMPH)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06.
What is AMPH's market cap?
Amphastar Pharmaceuticals, Inc. (AMPH) has a market capitalization of $880.74M as of 2026-06-30.
What is AMPH's P/E ratio?
Amphastar Pharmaceuticals, Inc. (AMPH)'s trailing twelve month P/E ratio is 11.21x as of 2026-06-30.
What is AMPH's EPS (earnings per share)?
Amphastar Pharmaceuticals, Inc. (AMPH)'s trailing twelve month EPS is $1.80 as of 2026-06-30.
What is AMPH's ROE (return on equity)?
Amphastar Pharmaceuticals, Inc. (AMPH)'s trailing twelve month Return on Equity (ROE) is 10.30% as of 2026-06-30.
What is AMPH's ROA (return on assets)?
Amphastar Pharmaceuticals, Inc. (AMPH)'s trailing twelve month Return on Assets (ROA) is 4.68% as of 2026-06-30.
What is AMPH's ROIC (return on invested capital)?
Amphastar Pharmaceuticals, Inc. (AMPH)'s trailing twelve month Return on Invested Capital (ROIC) is 7.45% as of 2026-06-30.
What is AMPH's EV/EBITDA?
Amphastar Pharmaceuticals, Inc. (AMPH)'s trailing twelve month EV/EBITDA is 8.67x as of 2026-06-30.